-
Product Insights
NewNet Present Value Model: PolyPid Ltd’s Doxycycline hyclate CR
Empower your strategies with our Net Present Value Model: PolyPid Ltd's Doxycycline hyclate CR report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Empagliflozin in Chronic Kidney Disease (Chronic Renal Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Empagliflozin in Chronic Kidney Disease (Chronic Renal Failure) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Empagliflozin in Chronic Kidney Disease (Chronic Renal Failure)...
-
Product Insights
Colon Carcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Colon Carcinoma - Drugs In Development, 2023’, provides an overview of the Colon Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Colon Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Plogosertib in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Plogosertib in Non-Small Cell Lung Cancer Drug Details: Plogosertib is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Talimogene Laherparepvec in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Talimogene Laherparepvec in Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Talimogene Laherparepvec in Breast Cancer Drug Details: Talimogene laherparepvec (Imlygic) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Doxycycline Hyclate Cr in Surgical Wound Infections
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDataÂ’s proprietary machine learning algorithms developed using over 10 years of historical data. Doxycycline Hyclate Cr in Surgical Wound Infections Drug Details: Doxycycline hyclate is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Siplizumab in Type 1 Diabetes (Juvenile Diabetes)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Siplizumab in Type 1 Diabetes (Juvenile Diabetes) Drug Details: Siplizumab is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Memantine Hydrochloride in Vascular Dementias
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Memantine Hydrochloride in Vascular Dementias report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Memantine Hydrochloride in Vascular DementiasDrug Details:Memantine Hydrochloride (Namenda / Ebixa / Axura...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vemurafenib in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vemurafenib in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vemurafenib in Refractory Multiple Myeloma Drug Details: Vemurafenib (Zelboraf, RG7204, PLX4032,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Decitabine in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Decitabine in Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Decitabine in Ovarian Cancer Drug Details: Decitabine (Dacogen/ Dake) is a 1,3,5-triazine...